All In Biotech

Drug Trial Radar · NCT07589634

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Dec 31, 2027

Study completion Jul 30, 2030

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.

Conditions

  • Multiple Myeloma

Interventions

  • RamantamigDrug

    Ramantamig will be administered as subcutaneous (SC) injection.

  • TocilizumabDrug

    Tocilizumab will be administered as intravenous (IV) injection.

  • PlaceboDrug

    Placebo (saline) will be administered as IV injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)Time frame: By the end of Day 28 from first ramantamig dose

Locations

60 sites in 10 countries. Site status is shown where the registry gives one.

  • City of Hope Phoenix

    Goodyear, Arizona · Recruiting

  • Beverly Hills Cancer Center (BHCC)

    Beverly Hills, California · Recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Stanford University Medical Center

    Palo Alto, California · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Washington University School Of Medicine

    St Louis, Missouri · Recruiting

  • Ohio Health Research Institute

    Columbus, Ohio · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Hospital Aleman

    Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming

    Buenos Aires, Argentina · Recruiting

  • Hospital Privado Centro Medico de Cordoba

    Córdoba, Argentina · Recruiting

  • Hospital Universitario Austral

    Pilar, Argentina · Recruiting

  • Flinders Medical Centre

    Bedford Park, Australia · Recruiting

  • Sunshine Coast University Hospital

    Birtinya, Australia · Recruiting

  • Concord Repatriation General Hospital

    Concord, Australia · Recruiting

  • St Vincents Hospital Melbourne

    Fitzroy, Australia · Recruiting

  • Wollongong Hospital

    Wollongong, Australia · Recruiting

  • Centre Hospitalier Victor Dupouy

    Argenteuil, France · Recruiting

  • Centre Hospitalier de la Cote Basque

    Bayonne, France · Recruiting

  • CHU de Grenoble

    La Tronche, France · Recruiting

  • Centre de Cancerologie de la Sarthe

    Le Mans, France · Recruiting

  • CHU Nantes - Hotel Dieu

    Nantes, France · Recruiting

  • Centre Hospitalier de Quimper Cornouaille

    Quimper, France · Recruiting

  • Uni General Hospital of Alexandroupolis

    Alexandroupoli, Greece · Recruiting

  • 251 Air Force General Hospital

    Athens, Greece · Recruiting

  • Alexandra General Hospital of Athens

    Athens, Greece · Recruiting

  • Metaxa Cancer Center Hospital Of Piraeus

    Piraeus, Greece · Recruiting

  • General University Hospital of Patras

    Rio, Greece · Recruiting

  • Theageneio Cancer Hospital

    Thessaloniki, Greece · Recruiting

  • Hippokration Hospital

    Thessaloniki, Greece · Recruiting

  • Semmelweis Egyetem

    Budapest, Hungary · Recruiting

  • Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely

    Budapest, Hungary · Recruiting

  • Orszagos Onkologiai Intezet

    Budapest, Hungary · Recruiting

  • Pecsi Tudomanyegyetem Klinikai Kozpont

    Pécs, Hungary · Recruiting

  • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar

    Szeged, Hungary · Recruiting

  • Hospital Ampang

    Ampang, Malaysia · Recruiting

  • Hospital Pulau Pinang

    George Town, Malaysia · Recruiting

  • Hospital Sultanah Aminah

    Johor Bharu, Malaysia · Recruiting

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.